On Oct 3, Nasdaq Notified That It Has Granted Oncternal Therapeutics Additional 180 Calendar Days To Regain Compliance With Minimum Bid Requirement
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics has been granted an additional 180 days by Nasdaq to regain compliance with the minimum bid requirement, according to an SEC filing.

October 06, 2023 | 8:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oncternal Therapeutics has been given more time by Nasdaq to meet the minimum bid requirement. This could potentially stabilize the company's stock in the short term.
The extension granted by Nasdaq provides Oncternal Therapeutics with more time to regain compliance with the minimum bid requirement. This could potentially prevent the company's stock from being delisted, which would likely have a negative impact on the stock price. Therefore, this news could stabilize the stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100